{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of January 2020): Undecided"],"condition":["HER-2 Positive Colorectal Cancer","Colorectal Neoplasms"],"disease":["Her-2 Positive Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2326840"],"location":["China"],"study_start_month":["1"],"keyword":["Capecitabine"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer","description":"To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with metastatic her-2 positive colorectal cancer after standard treatment.","dates":{"creation":"2020-01-15"},"accession":"2326840","cross_references":{"ClinicalTrials___gov":["NCT04227041"]}}